Koselugo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/10936
Periodic Safety Update EU Single assessment - 
26/10/2023 
n/a 
PRAC Recommendation - maintenance 
/202304 
selumetinib 
II/0013 
Update of sections 4.2 and 5.2 of the SmPC in order 
14/09/2023 
19/10/2023 
SmPC, Annex 
For more information, please refer to the Summary of 
to update the recommended dosage regimen to 
II and PL 
Product Characteristics. 
remove the fasting state and update pharmacokinetic 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
information, based on the final results from study 
D1346C00015; this is a phase 1, single-arm, 
sequential study to evaluate the effect of food on the 
gastrointestinal tolerability and pharmacokinetics of 
selumetinib after multiple doses in adolescent 
children with neurofibromatosis type 1 (NF1) related 
plexiform neurofibromas (PN). The Package Leaflet is 
updated accordingly. In addition, the MAH took the 
opportunity to introduce minor editorial changes to 
the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
R/0010 
Renewal of the marketing authorisation. 
30/03/2023 
31/05/2023 
SmPC, Annex 
The CHMP, having reviewed the available information on 
II and PL 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Koselugo, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
PSUSA/10936
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
/202210 
selumetinib 
N/0012 
Minor change in labelling or package leaflet not 
13/01/2023 
31/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10936
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202204 
selumetinib 
II/0006/G 
This was an application for a group of variations. 
13/10/2022 
n/a 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IA/0009 
B.I.b.2.a - Change in test procedure for AS or 
30/08/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
N/0008 
Minor change in labelling or package leaflet not 
18/07/2022 
31/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0005 
Minor change in labelling or package leaflet not 
29/06/2022 
31/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10936
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
selumetinib 
R/0003 
Renewal of the marketing authorisation. 
24/02/2022 
25/04/2022 
Annex II 
IB/0002 
C.I.11.z - Introduction of, or change(s) to, the 
19/10/2021 
25/04/2022 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
03/08/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 4/4 
 
 
 
 
 
 
 
 
 
